Key statistics
On Thursday, LENZ Therapeutics Inc (LENZ:NSQ) closed at 34.22, -12.11% below its 52-week high of 38.93, set on Nov 13, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 34.00 |
---|---|
High | 34.62 |
Low | 33.10 |
Bid | 32.81 |
Offer | 53.76 |
Previous close | 33.91 |
Average volume | 150.32k |
---|---|
Shares outstanding | 27.50m |
Free float | 26.73m |
P/E (TTM) | -- |
Market cap | 943.83m USD |
EPS (TTM) | -7.08 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 20:59 GMT.
More ▼
- LENZ Therapeutics to Participate in Upcoming Investor Conferences
- LENZ Therapeutics Reports Third Quarter 2024 Financial Results
- LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024
- CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100
- LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia
- LENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical Conferences
- LENZ Therapeutics Reports Second Quarter 2024 Financial Results
- LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia
- LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
- LENZ Therapeutics Announces $30 Million Investment from Ridgeback Capital
More ▼